Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Lei Lei Wu

News Reporter

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Ahead of FDA decision, Alnylam faces the big question: Can it make money?

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit

FDA staff return to White Oak campus en masse after Trump administration push

Servi­er pays $70M up­front for Black Di­a­mond’s RAS- and RAF-tar­get­ed can­cer drug

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug